Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model
Pseudomonas aeruginosa is the major infectious agent of concern for cystic fibrosis (CF) patients. Therefore, it is necessary to develop appropriate strategies for preventing colonization by this bacterium and/or neutralizing virulence factors. In this study, we formulated the encapsulation of exotoxin A into PLGA nanoparticles. The biological activities of the nanovaccine candidate were also characterized. Based on the results, ETA-PLGA can act as a suitable immunogen to stimulate the humoral and cellular immune response. The antibodies raised against ETA-PLGA significantly decreased bacterial titer in the spleens of the immunized mice after challenge with PAO1 strain, compared to the control groups. The encapsulation of PLGA into ETA led to a significantly higher production of INF-γ, TNF-α, IL-4, and IL-17A cytokine responses compared to the ETA group. ETA-PLGA enhanced IgG responses in immunized mice compared to ETA antigen. We concluded that encapsulation of Pseudomonas aeruginosa ETA to PLGA nanoparticles can increase its functional activity by decreasing the bacterial dissemination.
KeywordsExotoxin A Vaccine PLGA Pseudomonas aeruginosa
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest associated with the present manuscript.
- Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S (2011) Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 29:2131–2139. https://doi.org/10.1016/j.vaccine.2010.12.087 CrossRefPubMedPubMedCentralGoogle Scholar
- McEwan Deborah L, Kirienko Natalia V, Ausubel Frederick M (2012) Host translational inhibition by Pseudomonas aeruginosa exotoxin A triggers an immune Response in Caenorhabditis elegans. Cell Host Microbe 11:364–374. https://doi.org/10.1016/j.chom.2012.02.007 CrossRefPubMedPubMedCentralGoogle Scholar
- Schaefers MM, Duan B, Mizrahi B, Lu R, Reznor G, Kohane DS, Priebe GP (2018) PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. Vaccine 36:6926–6932. https://doi.org/10.1016/j.vaccine.2018.10.010 CrossRefPubMedGoogle Scholar
- Singh D, Somani VK, Aggarwal S, Bhatnagar R (2015) PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: a promising alternate to traditional adjuvants. Mol Immunol 68:272–279. https://doi.org/10.1016/j.molimm.2015.09.011 CrossRefPubMedGoogle Scholar
- Weber A, Zimmermann C, Mausberg AK, Dehmel T, Kieseier BC, Hartung H-P, Hofstetter HH (2016) Pseudomonas aeruginosa and its bacterial components influence the cytokine response in thymocytes and splenocytes. Infect Immun 84:1413–1423. https://doi.org/10.1128/IAI.00905-15 CrossRefPubMedPubMedCentralGoogle Scholar